Methods of treating pain using an IL-31 monoclonal antibody

• US 8,968,732 B2
• Filed: 12/19/2013
• Issued: 03/03/2015
• Est. Priority Date: 01/10/2006
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Yao, Yue, Bilsborough, Janine
• Primary Examiner(s): Saoud, Christine J
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US14/134,278
• Publication Number:
  US 20140127206A1
• Time in Patent Office: 439 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Claims

1. A method of treating pain in a patient comprising administering to the patient a monoclonal antibody or an antigen-binding fragment thereof that specifically binds to a polypeptide sequence of amino acid residues 27-164 of SEQ ID NO:

2, wherein after administration the patient'"'"'s pain is reduced.

2. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is humanized.

3. The method of claim 1, wherein the antigen-binding fragment thereof is selected from the group consisting of a single-chain antibody, a Fab fragment, a Fab′

fragment, and a F(ab′

)₂ fragment.

4. The method of claim 1, wherein the monoclonal antibody is a chimeric antibody.

5. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is produced by the hybridoma selected from the group consisting of:

a) the hybridoma having the ATCC Patent Deposit Designation PTA-6815;

b) the hybridoma having the ATCC Patent Deposit Designation PTA-6816;

c) the hybridoma having the ATCC Patent Deposit Designation PTA-6829;

d) the hybridoma having the ATCC Patent Deposit Designation PTA-6830;

e) the hybridoma having the ATCC Patent Deposit Designation PTA-6831;

f) the hybridoma having the ATCC Patent Deposit Designation PTA-6871;

g) the hybridoma having the ATCC Patent Deposit Designation PTA-6872;

h) the hybridoma having the ATCC Patent Deposit Designation PTA-6875; and

i) the hybridoma having the ATCC Patent Deposit Designation PTA-6873.

6. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is produced by the hybridoma having the ATCC Patent Deposit Designation PTA-6815.

7. The method of claim 5, wherein the monoclonal antibody or antigen-binding fragment thereof is humanized.

8. The method of claim 6, wherein the monoclonal antibody or antigen-binding fragment thereof is humanized.

9. The method of claim 8, wherein the monoclonal antibody comprises a human immunoglobulin constant region.

10. The method of claim 8, wherein the isotype of the monoclonal antibody is IgG1, IgG2, IgG3 or IgG4.

11. The method of claim 8, wherein the isotype of the monoclonal antibody is IgG4.

12. The method of claim 7, wherein the antigen-binding fragment thereof is selected from the group consisting of a single-chain antibody, a Fab fragment, a Fab′

fragment, and a F(ab′

)₂ fragment.

13. The method of claim 8, wherein the antigen-binding fragment thereof is selected from the group consisting of a single-chain antibody, a Fab fragment, a Fab′

fragment, and a F(ab′

)₂ fragment.